divendres, 17 de març del 2017

HeartFlow, Siemens Healthineers ink CAD diagnostic dev deal

Siemens Healthineers, HeartFlowSiemens (NYSE:SI) Healthineers and HeartFlow said yesterday they inked a global collaborative deal to develop a solution for diagnosing and managing patinets with suspected coronary artery disease.

The collaborative deal will join CT Scanners from Siemens Healthineers with HeartFlow’s FFRct Analysis fractional flow reserve software to create personalized 3D models of each patients’ arteries while computer algorithms simulate blood flow and look for arterial blockages.

“It is a fact that the treatment planning for coronary artery disease patients can be improved via quantitative data out of FFR measurements. With our exciting partnership between Siemens Healthineers and HeartFlow, Inc., we create an integrated solution that combines the exceptional cCTA images acquired by our high performance scanners with the only commercial product available that can derive FFR analysis noninvasively from CT data,” Siemens Healthineers computed tomography head André Hartung said in a press release.

The companies said that the combined clinical pathway of CT angiography and HeartFlow’s FFRct analysis can yield actionable information to help determine the patient’s optimal course of treatment.

“HeartFlow is pleased to collaborate with Siemens Healthineers, with its outstanding technology, tremendous expertise, and global reach Like HeartFlow, Siemens Healthineers is deeply committed to helping clinicians improve the patient experience and clinical outcomes while also helping them to reduce the total cost of healthcare. By working together, we can ensure this technology gets to every patient who can benefit from it,” CEO Dr. John Stevens said in a prepared statement.

The collaboration will focus initially on the US, with plans to expand into additional markets in the future.

The post HeartFlow, Siemens Healthineers ink CAD diagnostic dev deal appeared first on MassDevice.



from MassDevice http://ift.tt/2mb03Nj

Cap comentari:

Publica un comentari a l'entrada